Publications by authors named "Suzanne B Hendrix"

Claim this Profile
T
The impact of recent approvals on future alzheimer's disease clinical development: Statistical considerations for combination trials.
Samuel P Dickson, Craig Mallinckrodt, Aaron H Burstein, Laura Nisenbaum, Howard M Fillit, Suzanne B Hendrix

J Prev Alzheimers Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of AD04, an aluminum-based vaccine adjuvant, in patients with early Alzheimer's disease: Post hoc analysis of AFF006 (NCT01117818), a proof-of-concept, phase 2 randomized controlled trial.
Benjamin Haaland, Samuel P Dickson, Agustin Fernández Santana, Rudolph E Tanzi, Bruno Dubois, Suzanne B Hendrix

J Alzheimers Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer's disease.
Garrett B Duncan, Samuel P Dickson, Johanne M Kaplan, Samuel B Johnson, Tyler M Duke, Suzanne B Hendrix

Alzheimers Dement (N Y)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cohen-mansfield agitation inventory total score as a measure of agitation and aggression in Alzheimer's disease: A factor analysis.
Suzanne B Hendrix, Mary Sano, Constantine Lyketsos, Paul B Rosenberg, Anton P Porsteinsson

Int Psychogeriatr· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the ACTION-Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic Galactosemia.
Evan Bailey, Han Phan, Ayesha Ahmad, Janet Thomas, Elizabeth G Ames, Suzanne B Hendrix

J Clin Pharmacol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying Therapies.
Samuel P Dickson, Craig H Mallinckrodt, Basia Rogula, Lauren C Powell, Michele H Potashman, Suzanne B Hendrix

Neurol Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study.
Hui Jing Yu, Samuel P Dickson, Pei-Ning Wang, Ming-Jang Chiu, Chin-Chang Huang, Suzanne B Hendrix

EBioMedicine· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avoiding future controversies in the Alzheimer's disease space through understanding the aducanumab data and FDA review.
Samuel P Dickson, Sean Hennessey, Jessie Nicodemus Johnson, Newman Knowlton, Suzanne B Hendrix

Alzheimers Res Ther· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.
Alette M Wessels, Ellen B Dennehy, Sherie A Dowsett, Samuel P Dickson, Suzanne B Hendrix

Neurol Clin Pract· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GenoRisk: A polygenic risk score for Alzheimer's disease.
Samuel P Dickson, Suzanne B Hendrix, Bruce L Brown, Perry G Ridge, Jessie Nicodemus-Johnson

Alzheimers Dement (N Y)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on statistical strategies for the regulatory biomarker qualification process.
Suzanne B Hendrix, Robin Mogg, Sue Jane Wang, Aloka Chakravarty, Klaus Romero

Biomark Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Value-Generating Exploratory Trials in Neurodegenerative Dementias.
Lauren G Friedman, Nicholas McKeehan, Yuko Hara, Jeffrey L Cummings, Dawn C Matthews, Suzanne B Hendrix

Neurology· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease.
Hilkka Soininen, Alina Solomon, Pieter Jelle Visser, Suzanne B Hendrix, Kaj Blennow

Alzheimers Dement· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease.
Jessica B Langbaum, Noel N Ellison, Angelika Caputo, Ronald G Thomas, Carolyn Langlois, Suzanne B Hendrix

Alzheimers Res Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
Ana Espinosa, Montserrat Alegret, Pedro Pesini, Sergi Valero, Asunción Lafuente, Suzanne B Hendrix

J Alzheimers Dis· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial.
Hilkka Soininen, Alina Solomon, Pieter Jelle Visser, Suzanne B Hendrix, Kaj Blennow

Lancet Neurol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials.
Jinping Wang, Veronika Logovinsky, Suzanne B Hendrix, Stephanie H Stanworth, Carlos Perdomo

J Neurol Neurosurg Psychiatry· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis.
Alireza Atri, Suzanne B Hendrix, Vojislav Pejović, Robert K Hofbauer, John Edwards

Alzheimers Res Ther· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.
Jessica B Langbaum, Suzanne B Hendrix, Napatkamon Ayutyanont, Kewei Chen, Adam S Fleisher

Alzheimers Dement· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time.
Suzanne B Hendrix

Alzheimers Res Ther· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.
Napatkamon Ayutyanont, Jessica B S Langbaum, Suzanne B Hendrix, Kewei Chen, Adam S Fleisher

J Clin Psychiatry· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Separation of cognitive domains to improve prediction of progression from mild cognitive impairment to Alzheimer's disease.
Suzanne B Hendrix, Kathleen A Welsh-Bohmer

Alzheimers Res Ther· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Requiring an amyloid-β1-42 biomarker may improve the efficiency of a study, and simulations may help in planning studies.
Suzanne B Hendrix

Alzheimers Res Ther· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Gordon K Wilcock, Sandra E Black, Suzanne B Hendrix, Kenton H Zavitz, Edward A Swabb

Lancet Neurol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Witness and nonwitness children's violent and peaceful behavior in different types of simulated conflict with peers.
Bonnie Ballif-Spanvill, Claudia J Clayton, Suzanne B Hendrix

Am J Orthopsychiatry· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis